文献速递肿瘤 PET/CT核素与放射性配体治疗放射性药物与辐射防护

双标记曲妥珠单抗实现HER2阳性乳腺癌多模态影像引导手术

Multimodal image-guided surgery of HER2-positive breast cancer using [111In]In-DTPA-trastuzumab-IRDye800CW in an orthotopic breast tumor model.
PubMed 文献 · EJNMMI Res · 2019-11-21

该研究在HER2高表达的原位乳腺癌小鼠模型中,评估了[111In]In-DTPA-trastuzumab-IRDye800CW的双模态成像可行性。结果显示该双标记抗体在HER2阳性肿瘤中特异性高摄取(101 ± 7 %IA/g),而HER2低表达肿瘤摄取显著较低(1.2 ± 0.2 %IA/g,p = 0.007),并成功引导了肿瘤切除。

要点

  • 双标记曲妥珠单抗在HER2阳性肿瘤中特异性摄取,可被micro-SPECT/CT和荧光成像清晰显示。
  • HER2阳性BT474肿瘤摄取为101 ± 7 %IA/g,HER2低表达MCF7肿瘤摄取为1.2 ± 0.2 %IA/g(p = 0.007)。
  • 该双标记探针成功用于影像引导下的肿瘤切除,荧光信号与放射信号及HER2表达相对应。

核心结论

  • 双标记曲妥珠单抗在原位HER2阳性BT474乳腺癌肿瘤中特异性蓄积,micro-SPECT/CT和荧光成像均可清晰显示,并成功实现影像引导的肿瘤切除。

研究设计与样本

  • 在BALB/c裸鼠原位高HER2表达肿瘤模型中进行剂量递增(10、30、100 μg)的生物分布研究,注射后48小时测定。
  • 在低HER2表达乳腺癌模型中进行生物分布研究,并在各组进行多模态影像引导手术。
  • 对肿瘤切片进行放射自显影、荧光显微镜和免疫组化染色比较,评估肿瘤组织、HER2表达、荧光和放射信号的共定位。

主要发现

  • 基于生物分布数据,后续研究选择30 μg双标记曲妥珠单抗剂量(肿瘤与血液比值13 ± 2)。
  • [111In]In-DTPA-trastuzumab-IRDye800CW在原位HER2阳性BT474肿瘤中特异性蓄积(101 ± 7 %IA/g),而在原位低HER2表达MCF7肿瘤中摄取显著较低(1.2 ± 0.2 %IA/g,p = 0.007)。
  • BT474肿瘤可通过micro-SPECT/CT和荧光成像清晰可视化,并随后进行了影像引导切除。
  • BT474肿瘤的免疫组化分析显示荧光、放射信号与高HER2表达之间存在对应关系。

临床怎么用

  • 在临床环境中,[111In]In-DTPA-trastuzumab-IRDye800CW可能有助于通过SPECT/CT成像术前检测(转移性)肿瘤,并通过γ探头和荧光影像引导手术术中定位,以提高HER2阳性肿瘤患者的肿瘤根治性切除效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combining modalities using dual-labeled antibodies may allow preoperative and intraoperative tumor localization and could be used in image-guided surgery to improve complete tumor resection. Trastuzumab is a monoclonal antibody against the human epidermal growth factor-2 (HER2) receptor and dual-labeled trastuzumab with both a fluorophore (IRDye800CW) and a radioactive label (111In) can be used for multimodal imaging of HER2-positive breast cancer. The aim of this study was to demonstrate the feasibility of HER2-targeted multimodal imaging using [111In]In-DTPA-trastuzumab-IRDye800CW in an orthotopic breast cancer model. METHODS: Trastuzumab was conjugated with p-isothiocyanatobenzyl (ITC)-diethylenetriaminepentaacetic acid (DTPA) and IRDye800CW-NHS ester and subsequently labeled with 111In. In a dose escalation study, the biodistribution of 10, 30, and 100 μg [111In]In-DTPA-trastuzumab-IRDye800CW was determined 48 h after injection in BALB/c nude mice with orthotopic high HER2-expressing tumors. Also, a biodistribution study was performed in a low HER2-expressing breast cancer model. In addition, multimodal image-guided surgery was performed in each group. Autoradiography, fluorescence microscopy, and immunohistochemically stained slices of the tumors were compared for co-localization of tumor tissue, HER2 expression, fluorescence, and radiosignal. RESULTS: Based on the biodistribution data, a 30 μg dose of dual-labeled trastuzumab (tumor-to-blood ratio 13 ± 2) was chosen for all subsequent studies. [111In]In-DTPA-trastuzumab-IRDye800CW specifically accumulated in orthotopic HER2-positive BT474 tumors (101 ± 7 %IA/g), whereas uptake in orthotopic low HER2-expressing MCF7 tumor was significantly lower (1.2 ± 0.2 %IA/g, p = 0.007). BT474 tumors could clearly be visualized with both micro-SPECT/CT, fluorescence imaging and subsequently, image-guided resection was performed. Immunohistochemical analyses of BT474 tumors demonstrated correspondence in fluorescence, radiosignal, and high HER2 expression. CONCLUSIONS: Dual-labeled trastuzumab showed specific accumulation in orthotopic HER2-positive BT474 breast tumors with micro-SPECT/CT and fluorescence imaging and enabled image-guided tumor resection. In the clinical setting, [111In]In-DTPA-trastuzumab-IRDye800CW could be valuable for preoperative detection of (metastatic) tumors by SPECT/CT imaging, and intraoperative localization by using a gamma probe and fluorescence image-guided surgery to improve radical resection of tumor tissue in patients with HER2-positive tumors.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Deken MM, Bos DL, Tummers WSFJ, et al. Multimodal image-guided surgery of HER2-positive breast cancer using [111In]In-DTPA-trastuzumab-IRDye800CW in an orthotopic breast tumor model. EJNMMI Res. 2019. PMID: 31754913. doi:10.1186/s13550-019-0564-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。